Salmonella typhimurium hybrids expressing the S. typhosa antigens 9, d, and Vi were constructed by genetic crosses with an S. typhosa Hfr donor. The hybrids retained the same degree of mouse virulence as their S. typhimurium parent strain, the minimum lethal dose being less than 50 organisms when tested either in C57 black mice or Swiss white mice. Vaccination of the Swiss white mice with S. typhosa Ty2 vaccines prepared by acetone treatment, alcohol treatment, or heat-killing conferred significant protection against challenge by the hybrid strains but not against their S. typhimurium parent. Both the acetone-treated and alcohol-treated typhoid vaccines were markedly more protective than the heat-killed, phenol-preserved vaccine.
A number of investigators (1, 10) have shown that the active mouse protection test is unable to differentiate between the effectiveness of various typhoid vaccines for man. This lack of a meaningful, laboratory biological assay has handicapped both the selection and improvement of typhoid vaccines. Salmonella typhosa, highly pathogenic for man, exhibits only minimal virulence for experimental animals. It takes approximately 5 x 107 organisms to kill a mouse in 24 to 48 hr, and the death is due to toxemia rather than to infection. This may be the main reason why the results of animal potency tests do not reflect the value of typhoid vaccines for preventing typhoid in man.
A number of salmonellae, such as S. typhimurium, S. enteritidis, and S. moscow, are natural pathogens for the mouse, producing in them a systemic disease leading to septicemia which resembles typhoid infection in humans. We therefore considered the possibility of overcoming the inadequacies of S. typhosa as a challenge strain by producing, by conjugation between S. typhosa and S. typhimurium, a hybrid strain with the antigenic structure of S. typhosa and the pathogenicity (for the mouse) of S. typhimurium. The employment of such a hybrid as a challenge organism in a meaningful laboratory potency test for the efficacy of typhoid vaccines would require (i) that small numbers of the hybrid be able to produce in the mouse a typhoid-like infection, (ii) that the assay be able to detect differences in effectiveness between different lots and types of typhoid vaccines, and (iii) that the results of the animal tests should correlate with results of human field trials.
MATERIALS AND METHODS
Bacterial strains. The characteristics of the bacterial strains employed are shown in Table 1 . The derivation of the S. typhosa Hfr strain WR4000 (formerly called TD-7) has been described previously (3) . S. typhimurium Hfr strain WR4010 was derived from S. typhimurium WR5000 (formerly called HMXS) after two successive matings with S. typhosa Hfr WR4000. In the first of these matings, the met+ character of WR4000 was transferred to WR5000, and a met+ hybrid was selected which had also received the genetic locus-determining Vi antigen expression, viaB, as described previously (4) . This Vi antigenexpressing hybrid of S. typhimurium WR5000 was then remated with S. typhosa Hfr WR4000 to introduce the terminal lac+-linked sex factor, F, of the donor parent. Thus, the resulting hybrid, S. typhimurium WR4010, in addition to expressing the Vi antigen, is an Hfr donor with the same chromosome transfer orientation as S. typhosa WR4000.
Media. Minimal pension then was spread over the recipient lawn (also 0.1 ml/plate), either undiluted or in 10-fold dilutions depending upon the expected frequency of genetic transfer. Counterselection of the S. typhosa Hfr WR4000 was accomplished by the omission of cystine and tryptophan from the medium. S. typhimurium Hfr WR4010 was counterselected by the omission of histidine. Hybrids were picked from the mating plates and streaked for purification on media of the same composition as that used for their isolation. They were then examined for inheritance of unselected donor characteristics. Serological and biochemical analyses. Serological and biochemical studies were carried out by Rhoda Laidley, of the National Salmonella Centre, Laboratory Centre for Disease Control (LCDC), Ottawa, by the methods of Kaufmann (6) and Edwards and Ewing (2) .
Typhoid vaccines. The heat-killed vaccine was prepared by growing S. typhosa strain Ty2 on nutrient agar, harvesting after 16 hr, and preparing suspensions (10 international opacity units [IOU] ; 1 x 109 organisms/ml) which were then heated for 1 hr at 56 C (0.25% phenol was added as a preservative). Acetone-killed vaccine was made by shaking a suspension of S. typhosa Ty2 for 1 hr with three volumes of acetone and leaving it at room temperature for 3 days. After this time, the acetone was removed, and the bacteria were suspended in physiological saline (10 IOU) containing 1: 10,000 thimerosal. The alcohol-killed vaccines were prepared by essentially the same method as that for the acetone, by substituting 95% ethyl alcohol for the acetone.
Test for statistical significance. The results of assays were analyzed as R X C tables by using the usual chi-square criterion (9) .
RESULTS
Transfer of S. typhosa antigen determinants to S. typhimurium. S. typhimurium WR5004 was mated with the S. typhosa Hfr donor WR4000, and WR5004 hybrids were selected for receipt of the his+ marker of the donor. As reported previously (4, 5), the majority of his+-selected S. typhimurium hybrids obtained from mating with S. typhosa WR4000 also inherit the closely linked genetic determinant of somatic antigen 9. Because the genetic determinant of this antigen is the allele of the somatic antigen 4 determinant of S. typhimurium (4, 5, 8) , recombination of this locus results in loss of expression of antigen 4 by those S. typhimurium recombinants which express antigen 9. In addition, such recombinants also lose antigen 5 because this antigen cannot be expressed in strains lacking the determinant of antigen 4 (4, 5, 8) .
The genetic locus of the phase 1 flagellar antigen determinant of S. typhosa is sufficiently close to the his+ locus that some of the his+-selected hybrids of S. typhimurium undergo recombination at that locus as well (4) . Inasmuch as the phase 1 flagellar antigens of all Salmonella species comprise an allelic series at this locus (7), we were able to obtain his+ hybrids of S. typhimurium WR5004 which, in addition to antigen 9, expressed also the phase 1 flagellar antigen d of S. typhosa. As in the case of the somatic antigen, such hybrids lose their native phase 1 flagellar antigen, i.
The genetic determinant of the Vi antigen, viaB (4, 5), was introduced into two of the S. typhimurium WR5004 his+ hybrids (one expressing S. typhosa and antigen 9 and the other expressing S. typhosa antigens 9 and d) by mating with the Vi antigen-expressing S. typhimurium Hfr WR4010. Because of the considerable genetic map distance between the viaB locus and the nearest available selective marker in the S. typhimurium WR5004 hybrids (ara-), it was necessary to examine about 200 ara+ selected recombinants in each case to obtain a hybrid expressing the Vi antigen. The antigenic makeup of these two Vi-expressing hybrids, and a 9-antigen-expressing hybrid of WR5004, obtained from the cross with S. typhosa Hfr WR4000, are shown in Table 2 . As indicated here and described below, all hybrids HYBRID ASSAY OF TYPHOID VACCINES retained the virulence of the S. typhimurium WR5004 recipient.
Hybrids as model challenges. Sixteen-to 18-g C57 mice, bred at the LCDC, were used. Groups of 20 mice were infected intraperitoneally with graded doses of bacteria in a 0.5-ml volume. The mouse lethal dose (MLD) was less than 50 bacteria for each hybrid. Anatomopathological and bacteriological findings revealed that the hybrids caused both systemic infection and septicemia, with lesions appearing in several organs, especially the liver. The hybrids had therefore retained the pathogenicity ot the recipient parent strain S. typhimurium WR5004 and caused a true infection with a small challenge dose, thereby fulfilling the first requirement for the establishment of a model typhoid infection. Similar results were obtained using the LCDC strain of Swiss white mice (P.E.T.). All of the hybrids remained stable with regard to their inherited biochemical and antigenic characters; no loss or reversion of any of these characters was observed during infection in the mouse. The second requirement, regarding the ability of S. typhosa vaccines to protect against challenge was determined by immunizing intraperitoneally C57 mice with a dose of 0.5 ml of one of the three types of S. typhosa vaccine and by challenging 14 days later with 10 MLD of one of the hybrids. It was found, however, that this immunization, although prolonging the life of the mice, did not confer complete protection, as all of the mice died within the 21-day period of the experiment. The procedure was then repeated with the LCDC-bred Swiss white mice (P.E.T.), and again challenging with 10 MLD. With this breed of mice, a protective effect was observed over the full 21 days against challenge by each of the hybrid strains. The results of this experiment are shown in Table 3 . The least degree of protection was afforded by the heat-killed, phenol-preserved vaccine, which proved inferior in this regard to both acetone-and alcohol-treated products. None of the vaccines protected the mice against challenge by the parent S. typhimurium.
DISCUSSION
The development of mouse-virulent S. typhimurium hybrid strains expressing S. typhosa antigens has provided a number of challenge organisms which produce true systemic infection in mice. Employing these organisms, an assay procedure with LCDC Swiss white mice as the test animal has been developed which may allow differentiation of the protective capacities of different types of typhoid vaccines. The consistently higher protection which we observed with the acetone-treated vaccine is in keeping with clinical trials with humans. The lower level of protection afforded by the heat-killed vaccine, as compared to the alcohol b Acetone-treated vaccine was significantly more protective than the heat-killed product (P < 0.05).
VOL. 7, 1973 vaccine, is not in accordance with the results of reported field trials (1). This factor has to be studied since it is possible that our alcohol vaccines could have been substantially different from those used in the field trials.
The observation that the typhoid vaccines employed here were protective against the hybrid S. typhimurium strains which expressed S. typhosa antigens, but not against the S. typhimurium parent strain, is in agreement with the predicted r3sults if S. typhosa antigens are indeed involved in the immune mechanism. No significant differences were observed in our assay results among the challenge strains of S. typhimurium hybrids whether they contained only factor 9; 9, Vi; or the 9, Vi, d antigens. It would be premature at this stage to draw any conclusions with regard to the roles of the individual S. typhosa antigens, and, in fact, these experiments were not designed with that aim in mind. In this regard, the employment of purified Vi vaccines, as well as vaccines prepared from S. typhosa strains lacking the Vi antigen, as immunizing agents against these hybrid strains may prove illuminating.
Finally, it should be noted that the selection of the mouse strain for this assay was of critical importance. The virulence properties of the hybrids appeared to be identical in both the C,7 mice and the Swiss white mice, but there was a marked difference in the ability of the vaccines to protect the two mouse strains against challenge with these same hybrids. Protection was effective for the Swiss white mice over the 21-day observation period, but not for the C,7 mice. All of the latter died, and the immunization served only to bring about a delay in death. This would suggest that the C.7 mouse lacks the ability to develop a full immunological response against the challenge organisms.
